Insulin infusion via an intraosseous needle in diabetic ketoacidosis

K A Alawi1, G C Morrison, D D Fraser

  • 1Critical Care Unit, Department of Paediatrics, Children's Hospital of Western Ontario, University of Western Ontario and Children's Health Research Institute, London, Ontario, Canada.

Insights

Intraosseous insulin infusion effectively treated a child with severe diabetic ketoacidosis when IV access failed. This method offers a viable alternative for fluid and medication delivery in emergencies.

Area of Science:

  • Pediatric Endocrinology
  • Emergency Medicine
  • Critical Care

Background:

  • Severe diabetic ketoacidosis (DKA) in children presents significant management challenges, especially when intravenous (IV) access is difficult.
  • Current International Diabetes Society guidelines for DKA management do not explicitly mention intraosseous (IO) access.
  • Alternative routes like subcutaneous or intramuscular insulin may be less effective in critical DKA scenarios.

Observation:

  • A five-year-old child with severe DKA and dehydration could not obtain IV access at a remote hospital.
  • Initial resuscitative fluids and continuous insulin infusion were successfully administered via an intraosseous needle.
  • The patient's hyperglycemia and metabolic acidosis corrected rapidly, comparable to IV therapy, with no observed complications.

Findings:

  • Intraosseous administration of insulin and fluids is a feasible and effective alternative to IV therapy in pediatric DKA when IV access is unattainable.
  • The rate of correction for hyperglycemia and metabolic acidosis via IO route was comparable to traditional IV methods.
  • No adverse events were noted during or after the intraosseous treatment.

Implications:

  • IO access should be considered as a potential route for managing pediatric DKA with severe dehydration when IV access cannot be established.
  • Reviewing and potentially updating DKA management guidelines to include IO access could improve emergency care for critically ill children.
  • This approach ensures reliable delivery of essential resuscitation fluids and medications in challenging pediatric emergency situations.

Related Concept Videos

Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
Diabetic Ketoacidosis ll: Pathophysiology01:22

Diabetic Ketoacidosis ll: Pathophysiology

Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hyperosmolar Hyperglycemic State01:21

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...